Sevasemten Misses Primary Endpoint in Pivotal Trial for Becker Muscular Dystrophy

05 Nov 2026 0 comments

Servier reported that sevasemten did not meet its primary or secondary endpoints in the pivotal GRAND CANYON trial for Becker muscular dystrophy.

Source: NeurologyLive Published 05 Nov 2026 Imported 05 Nov 2026 Relevancy: Not reviewed

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.